Ferring Pharmaceuticals (Ferring) is a private, research-driven specialty biopharmaceutical company active in global markets. The company identifies, develops and markets innovative products in the fields of endocrinology, gastroenterology, infertility, obstetrics, urology and osteoarthritis.
In recent years Ferring has expanded beyond its traditional European base: with over 4,500 employees worldwide, it operates subsidiaries in over 50 countries and makes its products available in more than 90 countries.

The company has emerged as a world leader, with one of the largest peptide drug portfolios in the industry. Peptide drugs marketed by Ferring and/or licensees include: MINIRIN (desmopressin) for diabetes insipidus, primary nocturnal enuresis and nocturia; OCTOSTIM (high dose desmopressin) for hemophilia A and type I von Willebrand disease; GLYPRESSIN (terlipressin) for bleeding esophageal varices and hepatorenal syndrome; FIRMAGON (degarelix) for prostate cancer; PABAL/DURATOCIN (carbetocin injection) for post-partum bleeding; DECAPEPTYL SR (triptorelin) for prostate cancer; and TRACTOCILE (atosiban), for preterm labor.

Note not all Ferring products are available in all countries or territories. To learn more about Ferring products, please visit www.ferring.com. For a list of Ferring products sold in the US please visit www.ferringusa.com.

As part of its commitment to developing innovative products to treat diseases with high unmet medical need, Ferring invests heavily in its research infrastructure both in terms of people and technology.

Ferring Research Institute (FRI), headquartered in San Diego, California is a core component of Ferring’s research and innovation infrastructure. Established in 1996, FRI now occupies a company-owned, state-of-the-art research facility in Sorrento Valley. Located in the heart of the Southern California biopharmaceutical community, the center has attracted a diverse group of highly skilled professionals representing over fifteen countries of origin.

As the flagship research center for Ferring, scientists at FRI are focused on the following key therapeutic areas: reproductive health, urology, and gastroenterology. With capabilities in peptide pharmacology, biochemistry and preclinical in vivo modeling, FRI is committed to development of a portfolio of novel, innovative peptide pharmaceuticals to address areas of high unmet medical need.

In recent years, FRI researchers have developed six new peptide products (new chemical entities, NCEs), now at various stages of development, either in-house or through collaborations with partners. As a result, Ferring has today the largest portfolio of peptide therapeutics in the industry.

Peptide NCEs discovered by FRI include: FIRMAGON (degarelix) a self-depoting GnRH receptor antagonist marketed for the treatment of prostate cancer; barusiban (FE 200440), an oxytocin receptor antagonist; selepressin (FE 202158), a selective V1a receptor agonist; FE 200665, a peripherally-selective kappa opioid receptor agonist licensed to Cara Therapeutics; FE 202845, a long-acting peripherally-selective kappa opioid receptor agonist licensed to Cara Therapeutics; and FE 202767, a selective oxytocin receptor agonist.

In addition to its own drug discovery and development efforts, FRI works in close collaboration with world leading academic laboratories to translate new ideas emerging from basic research into innovative medicines.

FRI is an active supporter of the peptide research community, dedicated to the promotion of peptide research and development within both academia and industry. As part of this effort to engage with the global scientific network of peptide scientists, FRI is a founding sponsor of the Peptide Therapeutics Foundation which attracts premier peptide researchers at its Annual Peptide Therapeutics Symposium. To learn more about the Peptide Therapeutics Foundation, please click here: www.peptidetherapeutics.org